Home
Storia in 1 fonti
Novel dual-targeting biologic shows potential in treatment-naive wet AMD
Sunir J. Garg, MD, FACS, FASRS, spoke about TH103, a novel biologic targeting both VEGF and heparan sulfate proteoglycans, in treatment-naive patients with wet age-related macular degeneration in this video interview.Results from the phase 1 single ascending dose study of TH103 (Kalaris Therapeutics) were presented at the American Society of Retina Specialists annual meeting.
Raccontata da
healio.com
Timeline cronologica
- ·
Emerging treatments in wet AMD ‘moving beyond anti-VEGFs’
In this video, Vivienne S. Hau, MD, PhD, discussed a session presented at the American Society of Retina Specialists annual meeting on emerging durable treatments for wet…
- ·
Novel dual-targeting biologic shows potential in treatment-naive wet AMD
Sunir J. Garg, MD, FACS, FASRS, spoke about TH103, a novel biologic targeting both VEGF and heparan sulfate proteoglycans, in treatment-naive patients with wet age-related macular…